Seems you have not registered as a member of localhost.saystem.shop!
You may have to register before you can download all our books and magazines, click the sign up button below to create a free account.
The Politics of Cancer
This book examines the politics of cancer, explains how our government is intrinsically tied to cancer research efforts, and documents how major political actors make cancer policy and are influenced in their decision making by political, social, scientific, and economic variables. Is whether we contract cancer—and whether we survive the disease, if we get it—largely just a result of good versus bad luck, or are these outcomes regarding cancer tied to the policies and actions of our federal government? Cancer-treating drug development and approval is overseen by the U.S. Food and Drug Administration, billions of dollars of federal money are devoted towards cancer research, and exposure o...
Pathogenesis and Treatment of Leukemia
This book covers a comprehensive update on acute and chronic leukemia. In 54 chapters, authors introduce research progress and clinical trials of acute myeloid leukaemia (AML), acute promyelocytic leukaemia (APL), acute lymphoblastic leukaemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN) and chronic myeloid leukemia (CML). The last decade has seen the integration of genetic and clinical information to determine the prognosis and treatment strategies. This book provides practitioners, researchers and graduate students of Hematology and Hematopathology a comprehensive update on the pathobiology, genomics, classification, diagnosis, monitoring, prognostication and therapy of both acute and chronic leukemias.
Myelodysplastic Syndromes An Issue of Hematology/Oncology Clinics of North America
This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Topics discussed in this issue will include: Novel prognostic models for MDS, Evaluating MDS patients with genetic mutations that might be germline, Implications of splicing mutations in MDS for pathophysiology and therapy, Assessing quality of life in MDS/MPN overlap patients, Creation of a clinic for patients with clonal hematopoiesis, Luspatercept in MDS, Prospects for venetoclax in MDS, Treatment of acquired sideroblastic anemias, Treatment of patients with AML arising from MDS, Targeting TP53 mutations in MDS, among others.
When Blood Breaks Down
A leading cancer specialist tells the powerful stories of 3 adult leukemia patients—shining new light on the hidden history of the disease and the drugs developed to treat it. “A look at leukemia patients’ fear, survival and grace while fighting the disease . . . a quiet chronicle of life with and beyond leukemia, and sometimes life’s end.” —The Washington Post When you are told that you have leukemia, your world stops. Your brain can’t function. You are asked to make decisions about treatment almost immediately, when you are not in your right mind. And yet you pull yourself together and start asking questions. Beside you is your doctor, whose job it is to solve the awful puzzl...
Drugs and the FDA
How the FDA was shaped by public health crises and patient advocacy, told against a background of the contentious hearings on the breast cancer drug Avastin. Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer’s drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate US authority on a drug’s safety and efficacy? In Drugs and the FDA, Mikkael Sekeres—a leading oncologist and former chair of the FDA’s cancer drug advisory committee—tells the story of how the FDA became the most trusted regulatory agency in the world. It took a series of tragedies and health crises, as well as patient ...
Modernizing Medicare
Top policy experts offer Medicare reform solutions for the millions of seniors whose health care depends on America's fastest growing federal entitlement. In Modernizing Medicare, editors Robert Emmet Moffit and Marie Fishpaw bring together a rare combination of leading scholars and policy practitioners to outline a vision for Medicare reform and provide solutions for the millions of seniors whose health care depends on it. Contributors include a former Medicare trustee, a former Medicare administrator, and a former director of the Congressional Budget Office. Detailing Medicare's biggest problems, this team of top policy experts offer solutions based on personal freedom of choice, transpare...
Winning the War on Cancer
“A fascinating combination of personal story and details on the suppression of holistic cancer(and other disease) therapies” (Ann E. Fonfa, president, The Annie Appleseed Project). President Nixon signed the National Cancer Act in 1971, declaring a war on the disease. Nearly fifty years and several billion dollars later, it looks like we have lost the battle. Or have we? What if a natural solution had been there all along, just overlooked by the pharmaceutical industry? When a new, natural, and non-toxic way to address cancer is being discovered, it is a game changer that does not go unnoticed in the scientific community. But instead of being hailed and embraced, it is fiercely opposed b...
The Ethical Challenges of the Stem Cell Revolution
Stem cells, particularly pluripotent stem cells, hold significant promise for developing therapies for diseases and disorders for which there are no current treatments and for regenerating human cells, tissues, and possibly even organs. However, to be able to translate stem cell research into therapies, researchers must first address many scientific, ethical, and regulatory hurdles. The need for researchers and sponsors to demonstrate progress and the hopes of patient groups for new therapies have pressured researchers to move quickly into clinical trials and encouraged the opening of clinics offering unproven and unapproved stem cell treatments. This book tells the story of the development of the field, and identifies the ethical issues and challenges stem cell translation raises. It will be of interest to ethicists, scientists, and regulators working in the stem cell field, as well as the general reader following scientific developments.
Disorders of Hemoglobin
Completely revised new edition of the definitive reference on disorders of hemoglobin.
